Elexacaftor

CFTR corrector

Phase of research

FDA-approved for Cystic Fibrosis

How it helps

Restore CFTR Function

General information

Elexacaftor is a CFTR corrector molecule developed by Vertex Pharmaceuticals. In combination with the potentiator ivacaftor and corrector tezacaftor, it was approved for medical use in the USA in 2019 and sold under the name Trikafta™. In relation to cystic fibrosis, our AIM tool found the data that elexacaftor helps rescue F508del-CFTR.

Elexacaftor on PubChem
Elexacaftor on DrugBank
Elexacaftor on Wikipedia

Synonyms

VX-445

Marketed as

Dietary sources

N/A

Structure not available

C26H34F3N7O4S

Drug-Mutation Relation

results for F508del / R1162X
See all data on Elexacaftor

Treats

Mutation Link Tested on Impact factor Notes
F508del/F508del VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and tezacaftor. Better than only ivacaftor and tezacaftor.
F508del/R1162X VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and tezacaftor.

Does not treat

Mutation Link Tested on Impact factor Notes